Promising Results Propel Shares Higher as VK2735 Shows Potential for Significant Weight Reduction
Viking Therapeutics’ (VKTX) latest achievement in weight loss research has sparked enthusiasm among investors, with its experimental tablet demonstrating significant efficacy in reducing weight. The company’s shares surged by 15% in premarket trading following the announcement.
In a small early-stage trial, participants administered with Viking’s drug VK2735 experienced weight loss of up to 3.3%, surpassing Wall Street expectations. The oral tablet offers a convenient alternative to existing under-the-skin injections, aligning with patient preferences for ease of administration.
With plans to explore higher doses in subsequent trials and initiate mid-stage studies in obese patients later this year, Viking remains poised for further breakthroughs in weight management. The mild-to-moderate side effects reported indicate a promising safety profile, paving the way for continued development and potential commercialization.
Viking’s innovative approach to weight loss therapy, coupled with its commitment to addressing patient needs, underscores its position as a frontrunner in the biopharmaceutical industry. As the company progresses with its research, the prospect of offering effective oral treatments for obesity holds significant promise for patients seeking sustainable solutions to manage their weight.
Read original press release:here
You might like this article:Truth Social (DJT) Makes Striking Debut on Nasdaq, Surging Over 50%
